Oral abexinostat for relapsed lymphoma after two prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed diffuse large B-cell lymphoma (DLBCL) from a biopsy (histology).
- You have received exactly up to two prior standard treatment plans for DLBCL, including an anti-CD20 antibody plus chemotherapy or other cancer medicines.
- Your lymphoma either did not respond to the last treatment or grew/spread after the last treatment.
- You have at least one measurable lymphoma spot seen on scans (lymph node or tissue outside a node).
- You can do daily activities at a level that fits ECOG 0 to 2 (your study team will assess this).
- Your blood, liver, and kidney tests meet the study’s required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines glofitamab and selinexor to treat diffuse large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if this two-drug combination works better than standard options.
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
Hear when a new Diffuse Large B-cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.